
    
      Patients with advanced HCC will be enrolled and divided into two groups. Patients in
      experimental group will be treated with TACE combined with iNKT cells infusion. TACE will be
      performed at 0th and 4th week. iNKT cells will be infused at 1st, 3rd, 5th, 7th, 8th and 12th
      week. Patients in control group will be treated with TACE at 0th and 4th week. Adverse
      events（AEs）, overall survival (OS) time and recurrence-free survival (RFS) time, change of
      immune cells will be monitored.
    
  